If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somato ...

In the forests of upstate New York, little brown bats hang upside down in caves, sometimes for decades. One of them was once ...

Water makes up around 60% of the human body. More than half of this water sloshes around inside the cells that make up organs ...

Altum Sequencing, a start-up supported by the C3N-IA Science Park at Universidad Carlos III de Madrid (UC3M) and specialized ...

Learn how first-line antiepileptic drugs, personalized care, and lifestyle changes work together to manage generalized ...

Using a newly discovered byproduct of dying cancer cells, University of Wisconsin–Madison researchers are developing ...

The decision comes as the company is discontinuing clinical testing of a CLDN6-targeted CAR T-cell therapy in testicular cancer.

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

Researchers mapped Y chromosome loss across thousands of individual cells from human cancers, with disturbing results.

Yoseph Williamson, a Colorado Springs teen, is living with a rare genetic disorder that causes painful tumors on his nerve ...

At Miami-Dade’s public hospital system Jackson Health, new advancements in genetic research recently helped doctors modify a ...

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...